179 related articles for article (PubMed ID: 25001652)
21. The role of half-life of carcinoembryonic antigen (CEA) in prognosis prediction of colorectal cancer patients with preoperatively elevated CEA.
Yuan SQ; Zhou ZW; Wan DS; Chen G; Lu ZH; Wang GQ; Pan ZZ
Ai Zheng; 2008 Jun; 27(6):612-7. PubMed ID: 18570735
[TBL] [Abstract][Full Text] [Related]
22. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
23. Preoperative carcinoembryonic antigen elevation in colorectal cancer.
Yeh CY; Hsieh PS; Chiang JM; Lai CC; Chen JS; Wang JY; Hung HY
Hepatogastroenterology; 2011; 58(109):1171-6. PubMed ID: 21937372
[TBL] [Abstract][Full Text] [Related]
24. Is prostate-specific antigen still the best tumor marker for prostate cancer?
Leewansangtong S; Soontrapa S; Tantiwong A
J Med Assoc Thai; 1999 Oct; 82(10):1034-40. PubMed ID: 10561969
[TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of prognostic significance of molecular markers of apoptosis with clinical stage and tumor differentiation in patients with colorectal cancer: a single institute experience.
Ivanov K; Kolev N; Tonev A; Nikolova G; Krasnaliev I; Softova E; Tonchev A
Hepatogastroenterology; 2009; 56(89):94-8. PubMed ID: 19453036
[TBL] [Abstract][Full Text] [Related]
26. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
[TBL] [Abstract][Full Text] [Related]
27. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
28. Isolated tumor cells in lymph nodes are not a prognostic marker for patients with stage I and stage II colorectal cancer.
Lee MR; Hong CW; Yoon SN; Lim SB; Park KJ; Lee MJ; Kim WH; Park JG
J Surg Oncol; 2006 Jan; 93(1):13-8; discussion 18-9. PubMed ID: 16353185
[TBL] [Abstract][Full Text] [Related]
29. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis.
Arai T; Fujita K; Fujime M; Irimura T
Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558
[TBL] [Abstract][Full Text] [Related]
30. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
31. Biomolecular markers as determinants of patients selection for adjuvant chemotherapy of sporadic colorectal cancers.
Sudoyo AW
Acta Med Indones; 2010 Jan; 42(1):45-50. PubMed ID: 20737746
[TBL] [Abstract][Full Text] [Related]
32. Elevation of preoperative s-CEA concentration in stage IIA colorectal cancer can also be a high risk factor for stage II patients.
Kim CW; Yoon YS; Park IJ; Lim SB; Yu CS; Kim JC
Ann Surg Oncol; 2013 Sep; 20(9):2914-20. PubMed ID: 23760586
[TBL] [Abstract][Full Text] [Related]
33. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
35. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
36. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
37. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
38. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiation therapy.
Khil MS; Kim JH; Bricker LJ; Cerny JC
Cancer J Sci Am; 1997; 3(5):289-96. PubMed ID: 9327153
[TBL] [Abstract][Full Text] [Related]
39. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
Tarle M; Kovacić K; Kastelan M
Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
[TBL] [Abstract][Full Text] [Related]
40. Cytokeratin serum biomarkers in patients with colorectal cancer.
Holdenrieder S; Stieber P; Liska V; Treska V; Topolcan O; Dreslerova J; Matejka VM; Finek J; Holubec L
Anticancer Res; 2012 May; 32(5):1971-6. PubMed ID: 22593474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
